Harness Therapeutics Advances First‑in‑Class Huntington’s Disease Candidate HRN001 and Forms Expert Clinical Advisory Board

As reported on PharmaBiz, Harness Therapeutics has selected HRN001 as its lead therapeutic candidate for Huntington’s disease (HD), marking a major milestone for the company as it prepares to transition…

Continue Reading Harness Therapeutics Advances First‑in‑Class Huntington’s Disease Candidate HRN001 and Forms Expert Clinical Advisory Board

Monthly Obesity Treatment Gets Easier: Lilly’s New Zepbound Pen Simplifies Weight Loss Injections

Patients using Zepbound for weight management now have a simpler option for administering their medication. As reported by PharmaLive.com, Eli Lilly received FDA clearance for a redesigned injection pen that…

Continue Reading Monthly Obesity Treatment Gets Easier: Lilly’s New Zepbound Pen Simplifies Weight Loss Injections